language_icon
EN
HI

Onesource Specialty Pharma Share price

ONESOURCE

1867.4

12.90 (0.70%)
NSE
BSE
Last updated on 20 May, 2026 | 15:58 IST
Today's High

1905.00

Today's Low

1831.50

52 Week Low

1057.00

52 Week High

2248.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Onesource Specialty Pharma Chart

Onesource Specialty Pharma Share Key Metrics

Volume
2.69 L
Market Cap
21404.36 CR
LTQ@LTP
50@1867.40
ATP
1866.18
Var Margin
21.48 %
Circuit Range
1483.6-2225.4
Delivery %
45.33 %
Value
50.11 CR
ASM/GSM
No
Market Lot
1

Summary

Onesource Specialty Pharma share price is ₹1867.4 as of 20 May, 2026. The stock Onesource Specialty Pharma intraday movement has stayed between ₹1831.50 and ₹1905.00, while on a 52-week basis,Onesource Specialty Pharma price 52 week high is ₹2248.00 & its 52 week low is ₹1057.00.
In terms of trading activity, Onesource Specialty Pharma has recorded a volume of 268507 shares, The Onesource Specialty Pharma has a market cap of ₹114621201 CR. The stock’s Average Traded Price (ATP) stands at ₹1866.18, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 50 @ ₹1867.40.
Onesource Specialty Pharma operates within a circuit range of ₹1483.60 – ₹2225.40, with a Value of ₹50.11 CR. The Delivery Percentage for the day is 45.33%. Additionally, Onesource Specialty Pharma currently falls under the No framework, and trades with a market lot size of 1.

Onesource Specialty Pharma Fundamentals

View More
P/E Ratio

0

P/B Ratio

3.64

Div. Yield

0

Sector P/E

71.7

Sector P/B

3.51

Sec. Div. Yield

0.56

Onesource Specialty Pharma Resistance and Support

Pivot 1845.17

Resistance

First Resistance

1880.34

Second Resistance

1906.17

Third Resistance

1941.34

Support

First Support

1819.34

Second Support

1784.17

Third Support

1758.34

Onesource Specialty Pharma Shareholding Pattern

View More
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

30.48%

Mutual Fund

10.13%

Insurance

3.35%

Foreign Institutional Investors

17.5%

Domestic Institutional Investors

7.13%

Retail

31.41%

Others

0%

Total Promoters
MAR '26
30.48%

Onesource Specialty Pharma Corporate Actions

DateAgenda
2026-05-13Audited Results
2026-01-23Quarterly Results
2025-11-11Quarterly Results
2025-08-04Quarterly Results
2025-05-05Audited Results

Onesource Specialty Pharma News

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Ltd. released its Q4 and full year FY26 earnings call transcript. The company reported Q4 revenue of Rs.4,282 million and adjusted PAT of Rs.390 million, emphasizing strong sequential growth and the reaffirmation of its US$400 million FY28 organic revenue target.
May 19 2026 18:05:00

Onesource Specialty Pharma gets government nod for Unit II expansion project

Onesource Specialty Pharma has received in-principle approval from the Government of Karnataka for the expansion of its Unit II facility. This approval falls under the Karnataka Industrial Policy 2025–30 and includes incentives and concessions, aiming to enhance the company's manufacturing capacities to serve global partners.
May 16 2026 15:05:00

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Ltd received in-principle approval from the Government of Karnataka for its Unit II expansion project. This approval includes incentives and concessions under the Karnataka Industrial Policy 2025-30, aimed at enhancing manufacturing capacities for global partners.
May 16 2026 13:05:00

Onesource Specialty Pharma Ltd - 544292 - General-Update

Onesource Specialty Pharma secured in-principle approval from the Karnataka Government for its Unit II expansion project. This approval includes incentives and concessions under the KIP 2025-30, enhancing manufacturing capacities for global partners.
May 16 2026 13:05:00

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Onesource Specialty Pharma announced strong Q4 FY26 results with revenue growing 47% QoQ to Rs.4,282 million and EBITDA expanding over 5x. The company also reaffirmed its FY28 guidance.
May 13 2026 13:05:00

Onesource Specialty Pharma Ltd - 544292 - Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated May 13, 2026 For Approval Of The Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2026

Onesource Specialty Pharma board approved FY26 financial results, reporting a cons. net loss of ₹738.03 mn, significantly widening from ₹179.71 mn loss in FY25. Also appointed B S R & Co LLP as new statutory auditors for 5 years, replacing Deloitte Haskins & Sells.
May 13 2026 13:05:00

Onesource Specialty Pharma Ltd - 544292 - Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015

Onesource Specialty Pharma's Board of Directors is scheduled to meet on May 13, 2026. The agenda includes considering and approving the audited financial results for the quarter and year ended March 31, 2026.
May 07 2026 18:05:00

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Ltd. partner Orbicular received Health Canada approval for a generic version of Ozempic® (semaglutide injection). This enables commercialization for the first two generic entrants in Canada's significant semaglutide market, with OneSource supporting manufacturing from its US FDA-approved facility in Bengaluru.
May 04 2026 08:05:00

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Ltd. partner Orbicular received Health Canada approval for a generic version of Ozempic® (semaglutide injection). This enables commercialization for the first two generic entrants in Canada's significant semaglutide market, with OneSource supporting manufacturing from its US FDA-approved facility in Bengaluru.
May 04 2026 08:05:00

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

OneSource Specialty Pharma's partner, Orbicular, received Health Canada approval for a generic version of Ozempic (semaglutide injection). This enables commercialization in Canada's significant market, with OneSource providing manufacturing from its US FDA-approved facility, strengthening its CDMO presence.
May 04 2026 08:05:00
Read More

About Onesource Specialty Pharma

NSE : 29224  
BSE : 544292  
ISIN : INE013P01021  

Onesource Specialty Pharma Management

NamePosition
A TrishaCompany Secretary & Compliance Officer
Arun KumarChairman
View More

Onesource Specialty Pharma FAQs

The Buying Price of Onesource Specialty Pharma share is 1867.4 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Onesource Specialty Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Onesource Specialty Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Onesource Specialty Pharma shares is 0. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Onesource Specialty Pharma shares is 3.64. Useful to assess the stock's value relative to its book value.

To assess Onesource Specialty Pharma’s valuation compare Sector P/E, P/B which are 71.7 & 3.51 with sector averages, along with growth rates and financial metrics.

The Market Cap of Onesource Specialty Pharma is 21404.36 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Onesource Specialty Pharma share price is 2248.00 & 1057.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Onesource Specialty Pharma belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost